Ocugen (OCGN) to Release Quarterly Earnings on Thursday

Ocugen (NASDAQ:OCGN) is expected to issue its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Ocugen to post earnings of ($0.05) per share and revenue of $0.9760 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Friday, August 7, 2026 at 8:30 AM ET.

Ocugen (NASDAQ:OCGN) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.06) EPS for the quarter, missing the consensus estimate of ($0.05) by ($0.01). The business had revenue of $1.53 million during the quarter, compared to analysts’ expectations of $0.42 million. On average, analysts expect Ocugen to post $-0 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

Ocugen Price Performance

Shares of OCGN stock opened at $1.26 on Tuesday. Ocugen has a 12 month low of $0.93 and a 12 month high of $2.73. The company has a market capitalization of $426.54 million, a P/E ratio of -5.25 and a beta of 2.18. The stock has a 50 day moving average of $1.36 and a two-hundred day moving average of $1.59. The company has a current ratio of 1.86, a quick ratio of 1.86 and a debt-to-equity ratio of 4.17.

Insiders Place Their Bets

In related news, CFO Treerita Essali Johnson-Greene acquired 21,000 shares of the company’s stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average price of $1.23 per share, for a total transaction of $25,830.00. Following the transaction, the chief financial officer directly owned 521,000 shares of the company’s stock, valued at approximately $640,830. This trade represents a 4.20% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders own 3.95% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of OCGN. Vanguard Group Inc. raised its position in shares of Ocugen by 3.1% during the third quarter. Vanguard Group Inc. now owns 15,223,585 shares of the company’s stock worth $24,814,000 after acquiring an additional 450,904 shares during the last quarter. Millennium Management LLC lifted its position in Ocugen by 29.7% during the 4th quarter. Millennium Management LLC now owns 5,396,417 shares of the company’s stock valued at $7,285,000 after purchasing an additional 1,234,268 shares during the period. State Street Corp boosted its stake in shares of Ocugen by 193.6% in the 4th quarter. State Street Corp now owns 3,978,738 shares of the company’s stock valued at $5,371,000 after purchasing an additional 2,623,361 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Ocugen by 3.9% in the 4th quarter. Geode Capital Management LLC now owns 3,819,242 shares of the company’s stock valued at $5,159,000 after purchasing an additional 142,050 shares during the last quarter. Finally, Marshall Wace LLP acquired a new stake in shares of Ocugen during the 4th quarter worth approximately $3,417,000. 10.27% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

OCGN has been the topic of a number of recent research reports. Weiss Ratings downgraded shares of Ocugen from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, June 23rd. Wall Street Zen raised shares of Ocugen from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Finally, Canaccord Genuity Group lowered their target price on shares of Ocugen from $12.00 to $11.00 and set a “buy” rating on the stock in a research note on Wednesday, May 27th. Four investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $9.50.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.